Substance / Medication

Oxaprozin

Overview

Active Ingredient
oxaprozin
RxNorm CUI
32613

Indications

Oxaprozin tablets are indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis

Labeler: ST MARY'S MEDICAL PARK PHARMACYUpdated: 2025-12-17T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Cardiovascular Thrombotic Events Gastrointestinal Bleeding, Ulceration, and Perforation Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in

Contraindications

When this intervention should not be used

Oxaprozin is contraindicated in the following patients: 5.7 5.9 Warnings and Precautions (,) ] Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to oxaprozin or any components of the drug product [see 5.7 5.8 Warnings and Precautions (, ] History of asthma, urticaria,

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
[Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application].
Mao Mian, Wang Ling, Jiang Xuehua et al. · Sheng Wu Yi Xue Gong Cheng Xue Za Zhi · 2013
PMID: 23865335RCT
Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib.
Brinker Allen, Nourjah Parivash · Am J Health Syst Pharm · 2005
PMID: 15790802Observational
Transition metal(II) complexes with the non-steroidal anti-inflammatory drug oxaprozin: Characterization and biological profile.
Lazou Marialena, Hatzidimitriou Antonios G, Papadopoulos Athanasios N et al. · J Inorg Biochem · 2023
PMID: 36966675Other
Two Binding Sites of SARS-CoV-2 Macrodomain 3 Probed by Oxaprozin and Meclomen.
Li Jiao, Zhong Fumei, Li Mingwei et al. · J Med Chem · 2022
PMID: 36356292Other
Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism.
Willems Sabine, Busch Romy, Nawa Felix et al. · J Med Chem · 2024
PMID: 39081058Preclinical
Development and In vitro and In vivo Evaluations of a Microemulsion Formulation for the Oral Delivery of Oxaprozin.
Yin Fangming, Meng Shu, Zhao Xin et al. · Curr Drug Deliv · 2022
PMID: 34521326Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Oxaprozin (substance)
SNOMED CT
108518005
UMLS CUI
C0069739
RxNorm CUI
32613
Labeler
ST MARY'S MEDICAL PARK PHARMACY

Clinical Data

This intervention maps to 9 entities in the Ltrl knowledge graph.

4
Conditions
2
Biomarkers
1
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.